FlosatidilAlternative Names: SL 851016
Latest Information Update: 25 Oct 1995
At a glance
- Originator Sanofi-Synthelabo
- Class Antihypertensives; Antiplatelets; Ischaemic heart disorder therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Angina pectoris
Most Recent Events
- 25 Oct 1995 New profile
- 25 Oct 1995 Discontinued-II for Angina pectoris in European Union (Unknown route)